Performance evaluation of paediatric propofol pharmacokinetic models in healthy young children

P Sepúlveda1, L I Cortínez, C Sáez

  • 1Departamento de Anestesiología, Facultad de Medicina, Clínica Alemana Universidad del Desarrollo, Santiago, Chile.

Insights

Six of eight propofol pharmacokinetic models performed well in children aged 3-26 months using target-controlled infusions (TCIs). Most models overestimated initial volume, potentially leading to larger propofol bolus doses than needed.

Area of Science:

  • Anesthesiology
  • Pharmacokinetics
  • Pediatric Medicine

Background:

  • Assessing the performance of eight pediatric propofol pharmacokinetic models.
  • Focusing on target-controlled infusions (TCIs) in healthy children aged 3 to 26 months.

Purpose of the Study:

  • To evaluate the accuracy and bias of available propofol pharmacokinetic models in pediatric TCI.
  • To identify the best-performing model for use in young children.

Main Methods:

  • Studied 41 children (ASA I-II, 3-26 months) undergoing anesthesia.
  • Collected arterial blood samples at multiple time points during and after propofol administration.
  • Calculated median performance error (MDPE) and median absolute performance error (MDAPE) for model evaluation.

Main Results:

  • Model performance varied significantly across different stages of propofol administration.
  • Most models underestimated initial propofol concentrations, indicating overestimation of the volume of distribution.
  • Six out of eight models met performance criteria (MDPE < 20%, MDAPE < 30%), with the Short et al. model performing best.

Conclusions:

  • Six of the eight tested propofol pharmacokinetic models demonstrate adequate performance in young children for TCI.
  • Overestimation of initial volume of distribution by most models may lead to unnecessarily large propofol bolus doses.
  • The Short et al. model is recommended for TCI in this pediatric population.
Abstract

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetic Models: Comparison and Selection Criterion01:26

Pharmacokinetic Models: Comparison and Selection Criterion

Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
Pharmacokinetic Models: Overview01:20

Pharmacokinetic Models: Overview

Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal assumptions,...